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Simple Prognostic Criteria Can Definitively Identify Patients 
Who Develop Severe Versus Non-Severe Dengue Disease, 
or Have Other Febrile Illnesses
Andrew K.I. Falconara, b, Claudia M.E. Romero-Vivasa
Abstract
Background: Severe dengue disease (SDD) (DHF/DSS: dengue 
hemorrhagic fever/dengue shock syndrome) results from either 
primary or secondary dengue virus (DENV) infections, which oc-
cur 4 - 6 days after the onset of fever. As yet, there are no defini-
tive clinical or hematological criteria that can specifically identify 
SDD patients during the early acute febrile-phase of disease (day 
0 - 3: < 72 hours). This study was performed during a SDD (DHF/
DSS) epidemic to: 1) identify the DENV serotypes that caused 
SDD during primary or secondary DENV infections; 2) identify 
simple clinical and hematological criteria that could significantly 
discriminate between patients who subsequently developed SDD 
versus non-SDD (N-SDD), or had a non-DENV fever of unknown 
origin (FUO) during day 0 - 3 of fever; 3) assess whether DENV 
serotype co-infections resulted in SDD.
Methods: First serum samples, with clinical and hematological 
criteria, were collected from 100 patients during the early acute fe-
brile-phase (day 0 - 3: < 72 hours), assessed for DENV or FUO in-
fections by IgM- and IgG-capture ELISAs on paired serum samples 
and by DENV isolations, and subsequently graded as SDD, N-SDD 
or FUO patients.
Results: In this study: 1) Thirty-three patients had DENV infec-
tions, predominantly secondary DENV-2 infections, including each 
SDD (DHF/DSS) case; 2) Secondary DENV-2/-3 and DENV-2/-4 
serotype co-infections however resulted in N-SDD; 3) Each pa-
tient who subsequently developed SDD, but none of the others, 
displayed three clinical criteria: abdominal pain, conjunctival in-
jection and veni-puncture bleeding, therefore each of these criteria 
provided definitively significant prognostic (P < 0.001) values; 4) 
Petechia, positive tourniquet tests and hepatomegaly, and neutro-
philia or leukopenia also significantly identified those who: a) sub-
sequently developed SDD versus N-SDD, or had a FUO; b) subse-
quently developed SDD versus N-SDD; c) subsequently developed 
N-SDD versus FUOs, respectively.
Conclusions: This is the first report of simple definitively prog-
nostic criteria for SDD patients, including the first assessment and 
confirmation of conjunctival injection. The three definitive clinical 
criteria used alone, or supported by the other four criteria, could be 
essential for specifically identifying those patients needing prompt 
hospital-based therapies to lessen or avert SDD, without unneces-
sary hospitalization of the other patients.
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Introduction
There has been an alarming increase in the incidence of the 
vector-borne viral disease dengue fever (DF), and its severe 
life-threatening forms, dengue hemorrhagic fever/dengue 
shock syndrome (DHF/DSS) throughout tropical and sub-
tropical regions of the world [1]. Peak human infection rates 
occur after periods of increased rainfall due to increased 
replication of the principal dengue virus (DENV) mosquito 
vector species, Aedes aegypti [2]. Under-reporting or mis-
diagnosis of DENV infections often occurs due to both the 
lack of adequately equipped laboratories in many endemic 
areas, and the wide-range and over-lapping spectra of clini-
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cal symptoms of infections caused by DENV and other in-
fectious agents [3]. While most DENV-infected patients 
display an undifferentiated fever (DF: classical dengue fe-
ver), DENV infections may also result in thrombocytopenia, 
severe hemorrhage, and fatal shock [4], with some patients 
also developing hepatitis, myo-carditis, renal disease, respi-
ratory distress, encephalopathy or encephalitis [5]. Thus, 
new classifications were introduced to differentiate between 
patients with non-severe dengue disease (N-SDD) and those 
who develop warning signs (i.e. those requiring observation 
and medical intervention) and severe dengue disease (SDD) 
(severe plasma leakage (DHF), leading to shock (DSS), fluid 
accumulation with respiratory distress, severe bleeding, and/
or severe organ disease) [6].  
Serological assays, such as IgM and IgG capture ELI-
SAs are routinely employed for the diagnosis of DENV in-
fections but require paired patients’ S1 and S2 serum sam-
ples collected 2 - 14 days apart to confirm a greater than 
four-fold increase in DENV-specific IgG and/or IgM titers 
[4]. These assays are, however, usually negative within the 
first four days after the onset of fever in patients experienc-
ing primary DENV infections, with approximately 50% of 
them being IgM positive on day 5 [7]. Up to 32% of pa-
tients with secondary DENV infections may never generate 
detectable DENV-specific IgM antibodies [8]. Alternatively, 
DENV-infected patients may be identified by performing re-
verse transcription polymerase chain-reactions (RT-PCRs), 
or by DENV isolations using mosquito cell-lines, coupled 
with their detection using either RT-PCR or DENV antigen-
specific monoclonal antibodies (MAbs) [4, 6].
Since only a small proportion of patients with second-
ary DENV infections result in SDD (DHF/DSS) [9], many 
studies have been performed to identify clinical and hemato-
logical criteria that may discriminate between patients who 
have or will subsequently develop SDD (DHF/DSS) versus 
N-SDD (DF). In one study, aimed to identify early acute 
febrile phase prognostic markers in Colombia, there was a 
significant association between vomiting, gingival hemor-
rhage, microscopic hematuria and increased hematocrit, but 
not hepatomegaly, and subsequent SDD (DHF/DSS) devel-
opment [10]. In another Colombian study, age was identified 
as a major factor for the development of SDD but, whilst as-
cites, pleural effusion and bleeding, but not abdominal pain 
or vomiting, were also risk factors for the development of re-
spiratory distress and hypotension (SDD), the earliest day on 
which they were observed was not provided [11]. In contrast, 
a study of adults and older children (mean 34.7 ± 15.1 (range 
8 - 86 years old)) in Mexico, did not identify age as a SDD 
risk factor, but ascites, thrombocytopenia (40,000 - 60,000/
μl),  persistent  vomiting  and  some  symptoms  of  bleeding 
(e.g. gingivorrhagia and hematemesis), but not petechias, ec-
chymoses or a positive tourniquet test, were confirmed to 
be warning signs of imminent SDD [12]. In another study 
performed in Brazil, a positive tourniquet test, hematemesis 
and ecchymoses were found in SDD patients, but there was 
no correlation between thrombocytopenia on initial presen-
tation (hospital admission) and symptoms of bleeding [13]. 
Early adult DHF/DSS prognostic algorithms assessed in Sin-
gapore, either relied on real-time RT-PCR assays to assess 
DENV titers, which are too complicated and expensive to 
routinely perform [14], or only had a low (48.1%) predictive 
accuracy, and only prevented 43.9% of patients who only 
developed N-SDD (DF) from being unnecessarily hospital-
ized [15]. In a more recent study, using clinical laboratory 
data obtained from Thai patients less than 72 hours after the 
onset of fever in multivariable logistic regression models, 
age with minimum platelet and white blood cell counts, and 
maximum hematocrit and neutrophil percentages, aspartate 
aminotransferase (AST) concentrations and tourniquet test 
petechia numbers (> 20/inch2),  at  a  sensitivity  of  79.6%, 
could differentiate between patients who subsequently de-
veloped SDD (DHF/DSS) versus N-SDD (DF) [16]. In a 
more recent study also performed on data collected in Thai-
land, two different classification and regression tree (CART) 
analyses using algorithms that combined: 1) reduced white 
blood cell numbers, monocyte percentages and platelet num-
bers; and 2) increased hematocrits (CART #1) or, a) age (>   
6.75 years); b) reduced white blood cell numbers, neutrophil 
percentages, and platelet numbers; and c) increased aspar-
tate aminotransferase (AST) concentrations (CART #2) were 
tested for their abilities to identify patients who subsequently 
developed SDD (DSS or severe plasma leakage, respective-
ly) [17]. While these CART analyses could achieve a sensi-
tivity of 97% in identifying the DENV-infected patients who 
subsequently developed DSS, they only correctly excluded 
48%  of  those  who  subsequently  developed  N-SDD  (DF) 
[17].
Thus, because of the differences in the clinical and he-
matological findings observed in DENV infected patients 
who subsequently developed SDD (DHF/DSS) in studies 
conducted in the Americas and South-east Asia, and between 
studies conducted in the same countries, there is an urgent 
need to further evaluate criteria in different SDD (DHF/
DSS) endemic sites throughout the world. Simple clinical or 
hematological criteria that can identify such patients in poor 
SDD (DHF/DSS) endemic areas, that have poorly equipped 
laboratories, would be ideal so that prompt hospital-based 
supportive therapy can be provided to these patients to avert 
or reduce SDD.
In most of these previously described clinical studies 
[10-17], the abilities of each DENV serotype to cause SDD 
(DHF/DSS) in either primary or secondary DENV infec-
tions were not assessed. DHF/DSS epidemics began in the 
Americas after the introduction of virulent DENV-2 (Ameri-
can/Asian genotype) strains from Thailand that subsequently 
displaced more weakly pathogenic DENV-2 (American 
genotype) strains [18]. The DENV-3 Sri Lankan genotype 
IIIb strain was later introduced and which also caused DHF/
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DSS throughout the Americas [1], but virulent (DHF/DSS-
associated) DENV-3 Asian I and V genotype strains were 
also isolated in South America [19, 20]. While most cases of 
SDD (DHF/DSS) were previously associated with secondary 
DENV infections [9], many patients with primary infections, 
particularly with DENV-1 strains, also developed DHF/DSS 
[21]. More recently, there have been many reports in which 
patients with primary DENV infections developed SDD 
(DHF/DSS) in: 1) Thailand (primary DHF: 13.2%) [22], and 
which were predominantly caused by DENV-1 and DENV-
3 serotypes (primary DHF: DENV-1: 20%, DENV-3: 21%) 
[23] (primary DHF: DENV-1: 28%, DENV-3: 33%) [24]; 
2) Viet Nam, mainly caused by DENV-1 compared with 
DENV-2 (primary DHF: 18%) [25]; 3) Colombia, mainly by 
DENV-3, but less so by DENV-2 [26]; 4) Brazil, predomi-
nantly  by  DENV-3  (primary  DHF:  42.7%)  [27]  (primary 
DHF: 55.2%) [28]. It is therefore very important to deter-
mine whether SDD in patients resulted from either primary 
or secondary DENV infections, and to identify the DENV 
serotypes responsible in each case. We previously defined 
the terms ‘classical’ and ‘non-classical’ acute primary and 
secondary DENV antibody responses since the latter group 
included: 1) high S1 IgG acute primary (*P); 2) high S1 IgM 
acute secondary (*S); 3) high S1 IgM and low S2 IgG acute 
secondary (*LS) DENV infections [8]. As a result, the three 
previously published IgM:IgG (≥ 1.2 and < 1.2,  ≥ 1.4 and 
< 1.4 and ≥ 1.78 and < 1.78) discriminatory optical density 
(DOD) ratios could not reliably classify them using IgM:IgG 
OD ratios obtained from their early acute-phase (day 0 - 3: 
< 72 hour) S1 serum samples [8]. Higher ≥ 2.60 and < 2.60 
DOD ratios were therefore derived [8].  
We also reported the presence of DENV-1 and the viru-
lent DENV-2 American/Asian genotype strain (PTCOL96) 
(GenBank AF 163096.1) in the Magdalena River Valley of 
Colombia [29, 30]. DENV-1, DENV-2 and DENV-4 were 
subsequently shown to co-circulate in Barranquilla, which 
is the principal sea port of Colombia, during 2000 and 2001 
[8]. These DENV serotypes, of which DENV-4 was domi-
nant, were mainly identified in secondary DENV infections, 
but only caused N-SDD (DF) [8]. Cases of SDD (DHF/DSS) 
were, however, subsequently reported in Barranquilla.
In this study, we therefore tested: 1) whether SDD re-
sulted from either primary or secondary DENV infections; 
2) which DENV serotypes generated SDD in these patients; 
3) whether the patients who subsequently developed SDD 
(DHF/DSS) could be significantly differentiated from those 
who developed N-SDD (DF) or had a fever of unknown ori-
gin (FUO), during the early acute-phase of disease (day 0 
- 3: < 72 hours), using a panel of simple clinical and hema-
tological criteria; 4) whether patients infected with the viru-
lent (SDD-associated) DENV serotype strain would result in 
more severe clinically-graded disease when they were also 
co-infected with another DENV serotype; 5) whether any of 
these simple clinical or hematological criteria could also dis-
criminate between DENV-infected patients, and those who 
had an FUO.
Materials and Methods
Ethics statement
The Universidad del Norte Ethics Committee, following Co-
lombian national guidelines, approved this study involving 
human patients. Written consent was obtained from all of the 
patients, or in the case of children, from their parents before 
any patients’ samples or details were collected. 
Study area
Barranquilla, which has a population of 1.2 million people, 
is the principal sea-port of Colombia, and lies on the Carib-
bean coast at 14 meters above sea level. The average annual 
temperature is 28 oC, and two wet seasons occur throughout 
the year. This city is endemic for DENV transmission, with 
three of the four DENV serotypes previously found to co-
circulate [8]. This study was performed during a 2007 epi-
demic of SDD in the Por Fin district of Barranquilla. After 
written consent was obtained, first (S1) blood samples were 
collected from a total of 100 patients who presented at clin-
ics on either the day of onset of febrile illness (day 0), or 
day 1 to 3 (< 72 hours) after the onset of febrile illness. Full 
clinical details were obtained from each patient, hematologi-
cal studies were performed on the blood samples, and their 
serum samples were separated and stored at -85  oC. Each 
of these patients were subsequently followed up to record 
whether they required hospitalization, and 2 to 10 days after 
collecting their S1 samples, second (S2) blood samples were 
obtained from each of them. The hospitalized patients were 
further clinically classified on day 4 - 6 after the onset of 
symptoms as having SDD caused by DHF grades I, II, III 
and IV, without or with severe organ pathologies, according 
to strict WHO guidelines [4, 6]. As such, DHF I was deter-
mined by DF symptoms with thrombocytopenia (< 100,000/
μl), a positive tourniquet test and evidence of plasma leakage 
(≥ 20% increased hematocrit), DHF II was determined by 
DHF I criteria together with spontaneous bleeding, DHF III 
was determined by DHF I or II criteria with evidence of cir-
culatory failure (narrowed systolic pressure by < 20 mmHg 
(< 2.7 kPa), and DHF IV was determined by the criteria used 
for DHF I and II, together with evidence of profound shock 
(undetectable blood or pulse pressures) on day 4 - 6 after the 
onset of symptoms [4, 6]. 
Growth of DENV and identification of DENV serotypes
The use of DENV strains of each serotype for the ELISAs 
and the immuno-fluorescent assays (IFAs) were described 
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[8]. Briefly, DENV-1 (Nauru Island strain), DENV-2 (New 
Guinea-C prototype strain), DENV-3 (PR 1340 strain) and 
DENV-4 (Dominica strain) were grown in 70% confluent 
C6/36 (Aedes albopictus) cell monolayers, maintained in 
40 ml of Leibovitz (L-15) medium containing 10% (v/v) 
tryptose phosphate broth, 10% (v/v) fetal bovine serum and 
antibiotics in 80 cm2 culture flasks. After incubation at 28 
oC for 4 days, the supernatants were collected and replaced 
with fresh media and incubated for another 4 days to obtain 
a second harvest. These supernatants were made to 50 mM 
Tris/HCl pH 7.2, clarified by centrifugation at 200 × g, and 
aliquots were stored at -85 oC.  The cell pellets were re-sus-
pended in a minimal volume of PBS and added to each well 
of 12-well polytetrafluoroethylene (PTFE) coated immuno-
fluorescent slides (Hendley, UK), air-dried, fixed with cold 
(-20 oC) acetone, again air-dried and stored at -40 oC.  
The methods used for DENV isolation by cell-culture 
and  their  subsequent  detection  using  serotype-specific 
monoclonal antibodies (MAbs) were described [8]. Briefly, 
100 μl volumes of the patients’ S1 serum samples were 0.2 
μm filter-sterilized onto 70% confluent C6/36 (Aedes albop-
ictus) cell monolayers maintained in 2.5 ml cell culture me-
dium in 25 cm2 flasks. After incubation for 2 hours at 28 oC, 
the supernatants were collected and any detached cells were 
re-introduced into the flasks after centrifugation, discarding 
the supernatants, and re-suspending the cell-pellets in 10 ml 
of fresh media. After incubation at 28 oC for 7 - 10 days, the 
supernatants were harvested, made to 50 mM Tris/HCl pH 
7.2, clarified by centrifugation and stored at -85 oC. The cell 
pellets were re-suspended in a minimal volume of PBS, add-
ed to IFA slides, dried, fixed, re-dried and stored at -40 oC.
Immunofluorescent assays (IFAs)
Monoclonal antibodies (MAbs), specific for the envelope 
(E) glycoproteins of all flaviviruses (MAb 4G2), DENV-1 
(MAb 15F3), DENV-2 (MAb 3H5), DENV-3 (MAb 5D4) or 
DENV-4 (MAb 1H10) (ATCC, USA) were diluted to 1/100 
in  PBS  containing  2%  milk  powder  (Marvel,  Cadbury’s, 
UK) and reacted with the fixed C6/36 cells on the IFA slides 
for 2 hours at 28 oC. These slides were then washed three 
times with PBS and gently blotted before 10 μl of a 1/500 
dilution of FITC-labeled goat anti-mouse IgG (H&L) was 
added, and they were incubated at 28 oC for 1 hour. After 
washing three times with PBS, the slides were briefly dipped 
in distilled water, gently blotted, mounted with 90% (v/v) 
glycerol/PBS pH 8.3, and viewed under immuno-fluorescent 
microscopy using the appropriate FITC excitation and bar-
rier filters.
MAC and GAC ELISAs
The IgM- (MAC) and IgG- (GAG) capture ELISAs were 
described [8]. For these assays, 20 μg/ml of goat anti-human 
IgM (μ-chain specific) and anti human IgG (γ-chain specific) 
(109-005-129 and 109-005-098: Jackson ImmunoResearch, 
USA) were added at 50 μg/well in 1.6%/2.93% (w/v) sodium 
carbonate/bicarbonate buffer (pH 9.8) to high-binding ELI-
SA plates (Immulon 4, Dynatech, USA). These plates were 
then incubated overnight at 4 oC. After washing with PBS 
containing 0.05% (v/v) Tween 20 (P 1379; Sigma) (PBS/T), 
they were blocked using 120 μl/well of PBS containing 1% 
(w/v) gelatin (G 6650; Sigma) at 37 oC for 2 hours. Serial 
four-fold dilutions of patients’ sera, or control positive and 
negative patients’ sera, from 1/40 were prepared in triplicate 
in PBS/T with 0.25% gelatin (PBS/T/G) (140 μl volumes) in 
low binding ELISA plates (Immulon 1; Dynatech, USA). Af-
ter washing the blocked ELISA plate with PBS/T, 50 μl vol-
umes of the diluted sera were rapidly transferred to this plate 
working up the concentration gradients for IgM and IgG 
capture. After incubation at 37 oC for 2 hours, these plates 
were washed with PBS/T and a 1/3 dilution of the C6/36 
cell-culture supernatants infected with each of the four 
DENV serotypes, prepared in PBS/T/G (50 μl/well), were 
added and incubated at 37 oC to capture the DENVs. After 
washing again, a 1/60,000 dilution of purified MAb 2C5.1 
prepared in PBS/T/G was allowed to react with the captured 
DENV at 37 oC for 2 hours. After washing, the bound MAb 
was detected by sequential reaction steps with a peroxidase-
labeled goat anti-mouse IgG (H&L) second antibody (115-
035-062;  Jackson  ImmunoResearch,  USA),  and  0.012% 
(w/v) ο-phenylenediamine dihydrochloride (P 1526; Sigma) 
substrate in 0.09% (w/v) citrate-phosphate buffer (pH 5.0) 
containing 0.09% (v/v) H2O2 (50 μl/well). After incubation 
for 10 minutes, the reactions were stopped by the addition 
2M H2SO4 (25 μl/well) and absorbances were determined at 
dual 490 and 630 nm wavelengths (MRX; Dynex). Average 
optical density (OD) values for each dilution of positive and 
negative patients’ sera [8] were used to draw graphs and es-
tablish absorbance max/2 values for their 1/log10 50% end-
point IgM- and IgG-capture (MAC and GAC) ELISA titers 
(1/log10t50). Patients were reported to have current flavivirus 
infections when they showed greater than 4-fold increases 
in DENV-specific IgM or IgG 50% end-point titers titers (1/
log10t50) between their S1 and S2 serum samples. Primary or 
secondary DENV-infections were identified by applying ≥ 
2.6 and < 2.6 or ≥ 1.8 and < 1.8 discriminatory OD (DOD) 
ratios to their S1 and S2 sample IgM:IgG OD ratios obtained 
at 1/100 dilutions, respectively [8]. 
Statistical Analyses
The data were analyzed using EPIINFO 6.0 and compari-
sons between the clinical and hematological values of each 
group of patients were performed using Fisher’s exact test, 
from which two-tailed p values of < 0.05 were considered 
statistically significant. Comparisons of the mean ages of the 
patients who subsequently developed SDD or N-SDD, or 
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had a FUO were performed using the t-test for independent 
samples using MedCalc statistical software Version 11.6.
 
Results
Patients
For this study, 100 paired blood samples, in which their first 
(S1) samples were obtained on day 0 to 3 (< 72 hours) after 
the onset of febrile disease, were collected at out-patients 
clinics during a SDD (DHF/DSS) epidemic. Full clinical and 
hematological parameters were assessed upon presentation, 
which included the new WHO criteria for probable DENV 
infections: nausea, vomiting, rash, aches and pains, positive 
tourniquet test or leukopenia, with or without the ‘warning 
signs’ of abdominal pain or tenderness, persistent vomiting, 
clinical fluid accumulation, mucosal bleeding, liver enlarge-
ment (> 2 cm), increased hematocrit (% PCV), with concur-
rently decreased platelet numbers [6]. All patients were then 
further assessed, when second (S2) blood samples were ob-
tained from each of them 2 - 10 days later. Any hospitalized 
patients were diagnosed as having DHF grades I to IV or 
other symptoms of SDD, using strict WHO guidelines [4, 6]. 
Serological and virological results
Of the 100 patients samples collected in this study, most 
(67%: 67/100) had a fever of unknown origin (FUO), since 
they showed no reaction in the DENV IgM- and IgG-cap-
ture ELISAs using either their S1 or S2 serum samples. The 
others (33%: 33/100) were confirmed to have acute DENV 
infections by obtaining greater than 4-fold increase in their 
IgM- or IgG-capture ELISA titers (1/log10t50) between their 
S1 and S2 samples (Table 1). These patients ranged from 
1 - 27 years old, with their mean age being 8.1 years, and a 
male: female ratio of 0.94. Thus, predominantly young chil-
dren were infected during this SDD (DHF/DSS) epidemic. 
Most of these patients displayed ‘classical’ acute pri-
mary or secondary DENV antibody responses, which were, 
as previously found [8], most accurately identified in their 
S1 serum samples using the higher ≥ 2.6 and < 2.6 IgM: IgG 
discriminatory optical density (DOD) ratios, than the three 
other IgM: IgG (≥ 1.2 and < 1.2, ≥ 1.4 and < 1.4 and ≥ 1.8 
and < 1.8) DOD ratios previously published [8]. One patient 
(patient #5) was however erroneously identified as acute sec-
ondary DENV infections due to the low (0.4) IgM: IgG DOD 
ratio obtained using their S1 sample. Three other patients 
(patient #6, #11 and #15) were also erroneously identified as 
acute primary DENV infections due to their very high (4.3, 
3.0 and 3.0) IgM: IgG DOD ratios obtained using their S1 
samples. Thus, nearly all (91%: 30/33) of these cases were 
caused by secondary DENV infections, with one patient (pa-
tient #13) being classified as a low S2 IgG acute secondary 
infection (*LS), due to their lower S2 sample IgG than IgM 
ELISA titers (1/log10t50 = 3.5 versus 4.6). A low proportion 
(4/30: 13%) of patients with secondary DENV infections had 
DENV-specific IgM-negative S1 and S2 samples (patient # 
22, #23, #25 and #27), but which was lower than previously 
found in Barranquilla (12/27: 32%) [8]. 
DENV-1, DENV-2 or DENV-3 were isolated from the 
S1 samples of 19/33 (58%) of these patients, but DENV-2 
(90%: 17/19) was the dominant DENV serotype. Two pa-
tients (patient # 7 and # 25) were, however, co-infected 
with DENV-2/-3 and DENV-2/-4, respectively. All patients 
(patient # 2, #9, #10, #14 and #28) (5/33: 15%) that sub-
sequently developed SDD (DHF grades I to III), based on 
WHO criteria [4], had secondary DENV infections caused 
by DENV-2, which was therefore a highly virulent strain 
implicated in causing this SDD epidemic. The age range of 
these patients was 7 - 22 years old, with a male:female ratio 
of 0.6, while the most severe clinically-graded disease (DHF 
III = DSS) occurred in the youngest of these patients (patient 
# 28: 7 years old; patient # 9: 8 years old). Another twelve 
patients (patient # 3, #4, #6, #7, #11, #15, #16, #18, #21, 
#23, #24 and #25), who were also young children (age range 
6 - 11 years old), had secondary DENV infections caused by 
DENV-2, or co-infections caused by DENV-2 together with 
either DENV-3 (patient # 7) or DENV-4 (patient # 25), (both 
11 years old), but subsequently only developed non-severe 
dengue disease (N-SDD: DF). 
Clinical  and  hematological  criteria  obtained  from  pa-
tients upon presentation
All of these 33 DENV-infected patients (Table 1) were tested 
on the day of presentation (day 0 - 3 after the onset of febrile 
disease) using 20 clinical criteria and 10 hematological cri-
teria. While all of the results for the hematological criteria 
are shown, only the results for 12/20 of the clinical criteria 
are shown on Table 2. Since the average age of the patients 
who subsequently developed SDD (13.8 ± 6.4 years) was 
higher than those who developed N-SDD (8.8 ± 4.7 years), 
there was a low but significant difference between them (p = 
0.047). The average age of the patients with a FUO was how-
ever even higher (18.3 ± 15.8 years) and therefore a highly 
significant difference was obtained between these patients 
and those who developed N-SDD (p < 0.001). Amongst the 
other clinical criteria, hepatomegaly (< 2 cm) was observed 
in only 40% of the patients during the acute febrile phase 
of disease who subsequently developed SDD (DHF/DSS), 
but none of the other patients. Thus, this clinical criterion, 
observed in only some of these patients, was useful to sig-
nificantly discriminate between the patients who subsequent-
ly developed SDD, and those who developed N-SDD (p = 
0.02), or had a FUO (p = 0.003). 
Eight clinical criteria (abdominal pain, chills, conjunc-
tival injection, headache, joint pain (arthralgia), petechia, 
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No 
Age 
(y) 
DOCa
 Virusb 
1/log10 ELISA titer (OD at 1/100 dilution)c
Clinicald  
Classification
S1 IgM/IgG 
OD ratio 
(P/S)
S2 IgM/IgG 
OD ratio 
(P/S) S1 S2 IgM IgG IgM IgG
1 19 0 6 - - (0.4) - (0.7) 0.6(S) 3.5(1.5) 5.6(1.6) 0.9(S) N-SDD
2 14 1 9 D-2V - (0.2) - (0.5) 0.4(S) 4.1(1.6) 6.6(1.6) 1.0(S) SDD(DHF I)
3 10 1 4 D-2V - (0.5) - (0.3) 1.7(S) 3.2(1.3) 5.6(1.6) 0.8(S) N-SDD
4 6 1 5 D-2V - (0.4) - (0.2) 2.0(S) 3.3(1.5) 6.6(1.6) 0.9(S) N-SDD
5 7 1 4 - - (0.3) - (0.7) 0.4(S) 2.3(1.0) -(0.32) 3.1(*P) N-SDD
6 6 1 3 D-2V 3.2(1.3) - (0.3) 4.3(P) 3.2(1.4) 5.4(1.6) 0.9(*S) N-SDD
7 11 1 10 D-2/-3V - (0.6) 4.3(1.1) 0.6(S) 3.4(1.0) 6.3(1.6) 0.6(S) N-SDD
8 1 1 10 - - (0.7) - (0.2) 3.5(P) 2.9(1.3) - (0.3) 4.3(P) N-SDD
9 8 2 4 D-2V - (0.4) 4.2(1.2) 0.3(S) 2.9(1.0) 5.7(1.6) 0.6(S) SDD(DHF III)
10 22 2 7 D-2V - (0.2) 4.4(1.1) 0.2(S) 3.1(1.0) 6.7(1.6) 0.6(S) SDD(DHF II)
11 7 2 8 D-2V - (0.3) - (0.1) 3.0(P) 3.7(1.5) 4.9(1.5) 1.0(*S) N-SDD
12 9 2 6 - 2.1(0.9) 4.5(0.9) 1.0(S) 2.9(1.2) 6.0(1.6) 0.8(S) N-SDD
13 2 2 6 - - (0.5) - (0.3) 1.7(S) 4.6(1.6) 3.5(1.4) 1.1(*LS) N-SDD
14 18 2 8 D-2V - (0.3) 5.0(1.2) 0.3(S) 3.9(1.3) 5.8(1.6) 0.8(S) SDD(DHF II)
15 10 2 5 D-2V - (0.3) - (0.1) 3.0(P) 3.2(1.4) 4.9(1.5) 0.9(*S) N-SDD
16 8 2 8 D-2V - (0.4) - (0.2) 2.0(S) 3.6(1.6) 5.7(1.6) 1.0(S) N-SDD
17 10 2 5 - - (0.8) - (0.4) 2.0(S) 3.6(1.6) 6.6(1.6) 1.0(S) N-SDD
18 6 2 9 D-2V - (0.5) - (0.3) 1.7(S) 3.5(1.6) 5.6(1.6) 1.0(S) N-SDD
19 27 2 7 D-1V - (0.4) 4.2(0.8) 0.5(S) 2.9(1.0) 5.7(1.6) 0.6(S) N-SDD
20 11 2 8 - - (0.6) 4.6(1.0) 0.6(S) 3.2(1.3) 6.1(1.6) 0.8(S) N-SDD
21 6 2 4 D-2V - (0.3) -  (0.1) 3.0(P) 2.6(1.1) - (0.4) 2.8(P) N-SDD
22 14 2 5 D-3V - (0.3) -  (0.2) 1.5(S) - (0.8) 5.2(1.6) 0.5(S) N-SDD
23 9 2 8 D-2V - (0.3) 4.7(1.1) 0.3(S) - (0.6) 6.3(1.6) 0.4(S) N-SDD
24 6 3 5 D-2V - (0.6) - (0.7) 0.9(S) 3.6(1.6) 5.3(1.6) 1.0(S) N-SDD
25 11 3 9 D-2/-4V - (0.3) - (0.5) 0.6(S) - (0.5) 5.9(1.5) 0.3(S) N-SDD
26 11 3 9 - - (0.4) 2.1(0.9) 0.4(S) 2.3(0.9) 6.1(1.6) 0.6(S) N-SDD
27 11 3 13 - - (0.4) - (0.6) 0.7(S) - (0.7) 6.8(1.6) 0.4(S) N-SDD
28 7 3 6 D-2V - (0.2) - (0.6) 0.3(S) 3.0(1.1) 6.5(1.6) 0.7(S) SDD(DHF III)
29 6 3 5 - - (0.13) 4.5(1.4) 0.9(S) 3.5(1.3) 6.2(1.6) 0.8(S) N-SDD
30 11 3 5 - 2.8(1.0) - (0.6) 1.7(S) 3.7(1.3) 5.9(1.6) 0.8(S) N-SDD
31 7 3 5 - 3.5(1.6) 5.3(1.6) 1.0(S) 3.9(1.6) 6.2(1.6) 1.0(S) N-SDD
32 7 3 10 - 3.5(1.4) 5.0(1.6) 0.9(S) 4.0(1.6) 6.0(1.6) 1.0(S) N-SDD
33 7 3 10 - 1.7(0.9) 4.6(1.2) 0.8(S) 3.0(1.5) 5.9(1.6)  0.9(S)  N-SDD
Table 1. Viral and/or Serological Confirmation of DENV Infections in 33/100 Patients
aDOC: day of S1 and S2 serum collection after the onset of  fever. bDengue (-1 to -4) virus serotype isolated. cRecipro-
cal log10 50% end-point IgM and IgG ELISA titers and optical densities (ODs) at 1/100 dilutions (in brackets) to identify 
primary (P) or secondary (S) DENV infections using ≥ 2.6 and < 2.6 and ≥ 1.8 and < 1.8 IgM:IgG OD ratios on their S1 
and S2 samples, respectively, or high S1 IgG primary (*P), high S1 IgM secondary (*S) or low S2 IgG secondary (*LS) 
infections [8]. dClinical classifications as non-severe dengue disease (N-SDD) or severe dengue disease (SDD) with the 
DHF (I to IV) grade in brackets.
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positive tourniquet test, and veni-puncture bleeding) and two 
hematological criteria (lymphopenia and neutrophilia) were 
displayed by all five patients who subsequently developed 
SDD (DHF/DSS) (Table 2). Only three of these clinical cri-
teria (abdominal pain, conjunctival injection, and veni-punc-
ture bleeding) were not displayed by any of the patients who 
subsequently developed N-SDD or had a FUO, and therefore 
each of them yielded definitively significant discriminatory 
(P < 0.001) values. Petechia and a positive tourniquet test 
were also displayed by a low percentage of patients who 
subsequently developed N-SDD (petechia: 38.1%; positive 
tourniquet  test:  28.6%),  or  had  a  FUO  (petechia:  24.6%; 
positive tourniquet test: 20.8%), but both also gave highly 
significant discriminatory P = 0.02 and 0.03 (petechia) and 
0.005 and < 0.001 (positive tourniquet test) values for the 
SDD versus N-SDD or FUO patients, respectively. 
Each of the five patients who subsequently developed 
SDD also had neutrophilia, however this also occurred in 
23.8% and 50.7% of the patients who subsequently devel-
oped N-SDD or had a FUO, respectively. Statistical signifi-
cance (P = 0.03) was therefore only observed between the 
patients who subsequently developed SDD versus N-SDD.
Our  inability  to  find  a  significant  difference  between 
thrombocytopenia or increased hematocrits (≥ 20%) in the 
patients, during the early acute phase of disease (< 72 hours), 
who subsequently developed SDD versus N-SDD, or had a 
FUO was due to both criteria only being significantly dis-
played by these patients on day 4-6 after the onset of fever, 
when SDD (DHF I to III) occurred, in addition to reduced 
(< 20 mmHg) blood  pressures in patient #9 and #28 who 
developed DHF III (DSS).   
Despite only 60% and 62% of the patients who subse-
quently developed SDD and N-SDD displaying leukopenia, 
respectively, this criterion could significantly discriminate 
between those patients who subsequently developed N-SDD 
and those who had a FUO (N-SDD versus FUO: P = 0.001).
Additional DENV-associated complications (e.g. acute 
hepatitis, acute respiratory distress syndrome or encephalop-
athy/encephalitis) were not observed in any of the DENV-
infected patients in this study, despite being increasingly 
reported in Colombia [31-34] and elsewhere in the world [5].
Discussion
  
We previously isolated DENV-1, -2 and -4 serotypes in Bar-
ranquilla during 2000 and 2001, with DENV-4 being the 
most common, but without any SDD (DHF/DSS) cases [8]. 
In this study, only secondary DENV-2 infections were impli-
cated in the development of SDD (DHF/DSS). The DENV-2 
strain previously found in Barranquilla [8] (Romero-Vivas et 
al., unpublished), and further up the Magdelena River [30], 
were of the virulent American/Asian genotype, which caused 
the SDD (DHF/DSS) epidemic in Por Fin. During this study, 
DENV-2 was most frequently isolated, but DENV-3 was sub-
sequently imported and co-circulated with the other DENV 
serotypes. In another study conducted in North-east Colom-
bia, near the Venezuelan border, secondary DENV-2 infec-
tions were mainly associated with SDD, but some SDD also 
resulted from primary DENV-2 infections, while DENV-3 
induced SDD (DHF) occurred more frequently during pri-
mary DENV infections [26]. During 2001-2007, only strains 
of the DENV-3 IIIb genotype, were isolated in Colombia, 
and were different from those present in Brazil or Central 
American countries [35]. In another study, however, DENV-
3  genotype  I  was  identified  in  several  Colombian  states, 
while in three others DENV-3 genotype I and IIIb strains co-
circulated, but the  pathogenic capacities (SDD-associations) 
of these DENV-3 genotype I strains were not provided [19]. 
DENV-3 genotype V strains were also isolated in Colombia 
and Brazil, and caused a large SDD (DHF/DSS) epidemic in 
Brazil (Rio de Janairo) in 2002 [20]. As such, it is assumed 
that any DENV-3 isolates from Colombia are likely to be 
virulent, and may cause SDD in either primary or secondary 
DENV infections, as observed in both Colombia [26] and 
Brazil [27, 28]. DENV-3 genotype determinations of the iso-
lates from Atlantico (Barranquilla) have, however, not been 
obtained. 
A low number of SDD (DHF) cases were also caused 
by secondary DENV-1 infections in North-east Colombia, 
while no SDD cases were caused by DENV-4 [26]. While 
these results confirmed the presence of a virulent DENV-1 
genotype in this region of Colombia, only DENV-1 strains 
of the V/1 and V/2 genotype were widespread in Colombia, 
while one DENV-1 strain of genotype I had been isolated 
in the south of this country [36]. Further surveillance of the 
pathogenic capacities of DENV-1, DENV-2 and DENV-3, in 
Barranquilla is therefore urgently required. 
Despite their importance, few other studies have been 
performed to identify clinical or hematological criteria that 
can be used during the early acute phase of disease to sig-
nificantly discriminate between patients who subsequently 
developed either SDD versus N-SDD, or had a FUO. While 
we found three definitive clinical criteria (abdominal pain, 
conjunctival injection and veni-puncture bleeding), only one 
of them (abdominal pain) is included as a WHO ‘warning 
sign’ for potential SDD [6], while veni-puncture bleeding is 
not listed as a WHO ‘warning sign’, and conjunctival injec-
tion has not been assessed as a SDD prognostic criterion in 
any clinical study so far published. 
In two studies conducted in Colombia, the incidences 
of abdominal pain (57%), petechia (57%), positive tourni-
quet test (35%), and hepatomegaly (33%) in children with 
SDD (DHF/DSS) [31], and abdominal pain (67.5%), pete-
chia (60%) and veni-puncture bleeding (24.4%) in all SDD 
(DHF/DSS) patients [37] were lower than those found in 
our study. Age was also a SDD (DHF/DSS) risk-factor in 
other studies conducted in Colombia [11], Brazil [27] and 
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Clinical/hematological criteria 
 SDD         
( n   =   5 )                                     
N-SDD        
(n = 28 )
FUO           
(n = 67)
p-value  
  SDD  vs       
N-SDD  
SDD vs 
FUO
N-SDD 
vs FUO
Mean age (years) sd (range)
13.8 ±  6.4       
(7 - 22) 
8.8 ± 4.7            
(1 - 19) 
18.3 ± 15.8      
(0.5 - 59) 
0.047 ns < 0.001
Abdominal pain (%) 100.0 0.0 0.0 < 0.001 < 0.001 ns
Eye pain (%) 80.0 76.2 56.7 ns ns ns
Joint pain (arthralgia) (%) 100.0 76.2 73.1 ns ns ns
Hepatomegaly > 2cm (%) 40.0 0.0 0.0 0.02 0.003 ns
Jaundice (%) 0.0 0.0 20.9 ns ns ns
Vomiting (persistent) (%) 80.0 47.6 55.2 ns ns ns
Conjunctival injection (%) 100.0 0.0 0.0 < 0.001 < 0.001 ns
Gum bleeding (%) 20.0 9.5 4.5 ns ns ns
Petechia (%) 100.0 38.1 24.6 0.02 0.001 ns
Tourniquet test positive (%)a 100.0 28.6 20.8 ns < 0.001 ns
Venipuncture bleeding (%) 100.0 0.0 0.0 < 0.001 < 0.001 ns
Mean leukocytes (x103/µl)  sd (range)  
4.3 ± 1.0       
(3.1 - 5.8) 
5.0 ± 1.8         
(1.7 - 8.0)
8.0 ± 5.4          
(7.2 - 35.3)
- - -
Leukopenia (%)b 60.0 62.0 17.8 ns  ns 0.001
Leukocytosis (%)c  0.0 0.0 28.6 ns  ns  ns 
Mean lymphocytes (%) sd (range)
11.8 ± 6.3     
(4.3 - 18.6)
33.0 ± 12.6   
(12.1 - 58.3)
30.4 ± 17.9      
(6.6 - 35.4)
- - -
Lymphocytosis (%) 0.0 14.0 9.5 ns ns ns
Lymphopenia (%) 100.0 66.7 51.4 ns ns ns
Mean monocytes (%) sd (range)
4.6 ± 2.8       
(1.5 - 8.5)
9.8 ± 4.6         
(0.9 - 22.8)
8.3 ± 4.7          
(0.5 - 28.6)
- - -
Monocytosis (%) 40.0 81.0 59.2 ns ns ns
Monocytopenia (%) 0.0 4.8 5.6 ns ns ns
Mean neutrophils (%) sd (range) 
83.1 ± 7.8   
(76.6 - 89.9)
57.4 ± 15.7   
(27.9 - 85.5)
57.7 ± 20.7    
(21.1 - 95.5)
- - -
Neutropenia (%)d 0.0 28.6 9.3 ns ns ns
Neutrophilia (%)e 100.0 23.8 50.7 0.003  ns  ns
Mean platelets (x103/µl) sd (range)
136.6 ± 43.1    
(73.0 - 202.0)
226.4 ± 157.8 
(134.0 - 
393.0)
253.2 ± 114.0 
(128.0 - 527.0)
- - -
Thrombocytopenia (%)f 20.0  0.0 0.0 ns ns ns 
Mean hematocrit (%) sd (range)
35.6 + 5.2   
(28.0 - 41.3)
36.0 ± 3.3     
(27.8 - 40.9)
36.1 ± 4.8      
(33.7 - 38.6)
- - -
Haematocrit > 20% (%) 0.0 0.0 0.0 ns ns ns
Table 2. Early Acute Phase- (< 72 Hour-) Clinical and Hematological Criteria of Patients Who Subsequently Developed 
Severe Dengue Disease (SDD) or Non-Severe Dengue Disease (N-SDD), or Had Fever of Unknown Origin (FUO)
Clinical or hematological criteria percentages, numbers, standard deviations (sd: +) and ranges (in brackets), with com-
parative p-values or non-significant differences (ns). WHO values for DENV infections are:  apositive tourniquet test: 
>20 petechia/ inch2; bleukopenia: < 5,000/μl; cleukocytosis: > 10,000/μl; dneutropenia: < 40%; eneutrophilia: > 70%, and 
fthrombocytopenia: < 100,000/μl [4, 6].
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Thailand [17], but not in another study conducted in Colom-
bia [37] or in Mexico [12]. In our study, age only weakly 
discriminated between the patients who subsequently devel-
oped SDD and N-SDD (P = 0.047) but strongly between the 
N-SDD patients and those with a FUO (P < 0.001). 
We  did  not  find  that  fever,  exanthema,  thrombocyto-
penia (< 150,000), leukopenia (< 4,000) or vomiting were 
criteria to differentiate between patients who subsequently 
developed SDD versus N-SDD, as found in Brazil [39]. In 
another study, leukocyte count (< 4,500/μl) and thrombo-
cyte count (< 90,000/μl), but not positive tourniquet test, 
were associated with spontaneous bleeding in patients from 
a DENV-endemic area [40]. We did not, however, observe 
a correlation between thrombocyte numbers and bleed-
ing, as was also found in a study conducted in Brazil [13], 
since only one patient (patient #14) had thrombocytopenia 
(73,000/μl) upon presentation, while all of the patients who 
subsequently developed SDD  each displayed conjunctival 
injection, petechia and veni-puncture bleeding. In another 
study, conducted in southern Colombia (Neiva), there was a 
correlation between thrombocytopenia (< 20,000/μl) on the 
day of hospitalization and the subsequent development of 
shock (DSS) [33]. However, we observed thrombocyte num-
bers of 152,000 and 267,000 in patient #9 and #28 on the day 
of presentation (day 2 and 3 respectively), which dropped to 
49,000 and 23,000 on day 4 and 5 respectively after the onset 
of fever when they developed shock (DSS: DHF III). 
We also did not identify any DENV-infected patients that 
displayed abnormal clinical manifestations, as have been re-
ported elsewhere in Colombia (e.g. hepatitis or neurological 
(encephalopathy/encephalitis), renal, cardiac (myo-carditis), 
pancreatic, or pulmonary disease) [31-34], and elsewhere in 
the world [5]. 
While CART analyses achieved a sensitivity of 97% for 
identifying the DENV-infected patients who subsequently 
developed DSS using data collected < 72 hours after the 
onset of fever, they only correctly excluded 48% of those 
who subsequently developed N-SDD (DF) [17]. In contrast, 
we identified simple clinical and hematological criteria that 
could completely discriminate between patients, during the 
< 72 hour period, who subsequently developed SDD (DHF/
DSS) versus N-SDD, or had a FUO. These three simple, de-
finitive clinical criteria (abdominal pain, conjunctival injec-
tion and veni-puncture bleeding), together with petechia, a 
positive tourniquet test, and neutrophilia, that were also sig-
nificantly displayed by each of these patients, with or with-
out hepatomegaly, will be extremely valuable to definitively 
identify the patients who will subsequently develop SDD, 
amongst the much larger numbers who will subsequently 
develop N-SDD, or have a FUO. Importantly, these criteria 
can easily be assessed in poorly equipped clinics, as are pres-
ent throughout our study area, so that prompt hospital-based 
support therapy can be performed to lessen or avert the onset 
of SDD (DHF/DSS). Biochemical tests to identify increased 
creatinine kinase (CK) and lactate dehydrogenase (LDH), 
and reduced serum albumin (SA) concentrations [38], and 
increased aspartate aminotransferase (AST) concentrations 
[17] should be assessed in these hospitalized patients, due to 
their additional SDD-prognostic values [17, 38]. 
In a review of 15 studies that compared clinical and 
hematological criteria of patients with infection caused by 
DENV or FUOs, patients with DENV infections had signifi-
cantly lower platelet, white blood cell and neutrophil num-
bers, and high incidences of petechia [41]. In a further study 
performed in Thailand, minimum leukocyte (< 500/μl) and 
thrombocyte  (<  25,000/μl)  numbers,  and  maximum  neu-
trophil (> 75%) percentages, AST (> 100 U/dL) concentra-
tions and petechial (> 20/inch2) numbers in tourniquet tests, 
yielded the greatest odds ratios between patients infected 
with DENV and those with a FUO [17]. The new WHO cri-
teria for the specific identification of DENV infections now 
include nausea, vomiting, rash, aches and pains, positive 
tourniquet test, or leukopenia [6]. However, we found that 
leukopenia (< 5,000/μl) could only significantly differentiate 
between patients who developed N-SDD and those who had 
a FUO.
Co-infections with different DENV serotypes are rare, 
since the requirement to infect these patients during the rela-
tively short (5 - 7 (range 3 - 14) day) incubation period [4]. 
Therefore, only a few of these DENV co-infections have 
been confirmed in Asia (DENV-2/-3 and DENV-3/-4) [42] 
and the Americas (DENV-2/-3 and DENV-3/-4) [43], but no 
information was provided about whether increased disease 
severity was observed in these patients. Although homolo-
gous DENV genetic recombination events have been exten-
sively documented [44-46], there have not yet been any re-
ports of heterologous DENV-serotype recombination events. 
The potential of such events to result in new chimeric strains 
with a possibly greater ability to effect antibody-enhanced 
replication (AER), resulting in antibody-enhanced disease 
(AED) [47], needs to be investigated. 
Different human leukocyte antigens (HLAs) and non-
HLA  gene  polymorphisms  were  identified  as  risk  factors 
for developing SDD (DHF/DSS) in different countries [48]. 
While most studies identified different HLA class I mol-
ecules associated with both DHF/DSS risk and protection, 
HLA DR4, which occurs at a high frequency in Amerindian 
populations, provided protection against SDD (DHF/DSS) 
[49]. In a Mexican mestizo population, HLA-DQB1*0302, 
which also occurs at a high frequency in Amerindians, was, 
in contrast, positively associated with DHF/DSS risk and 
negatively associated with DF [50], while as yet unidenti-
fied genes provided SDD (DHF/DSS) resistance in the black 
populations from Cuba and Brazil [51, 52]. Our study site 
has a mainly mestizo population, but also a high percentage 
of the black (African) phenotype. As such, the differences 
in clinical and hematological criteria identified in our study 
and those reported previously, particularly from South-east 
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Asia [16, 17], may also result from differences in the DENV 
genotypes co-circulating in Colombia and southern South-
east Asian countries [53], and/or the patients’ genetics. All of 
the DHF/DSS patients identified in our study were of mes-
tizo phenotype and were all successfully treated in hospital.
Conclusions
Nine important findings came from this study, namely: 1) 
only secondary DENV infections with DENV-2 resulted in 
SDD (DHF/DSS); 2) secondary DENV co-infections with 
DENV-2/-3 or DENV-2/-4 did not result in SDD (DHF/DSS) 
in the few cases observed; 3) despite finding only low num-
bers of patients who developed SDD (DHF/DSS), we identi-
fied three definitive clinical criteria that were displayed by 
each of these patients during the early acute phase of disease 
(< 72 hours after the onset of fever), but not by any of the 
patients who developed N-SDD or had a FUO; 4) despite 
conjunctival injection not being previously assessed, we 
found that this was a definitive criterion for the development 
of SDD; 5) these clinical criteria where further significantly 
supported since each of these patients also displayed pete-
chia and yielded a positive tourniquet test; 6) neutrophilia 
and hepatomegaly could discriminate between the patients 
who subsequently developed SDD and N-SDD, and hepato-
megaly could also discriminate between the SDD and FUO 
patients; 7) age could only weakly discriminate between the 
SDD and N-SDD patients; 8) leukopenia could significantly 
discriminate between the DENV-infected patients and those 
who had a FUO; 9) thrombocytopenia and hemo-concentra-
tion, which are both sine qua non criteria for DHF, as well as 
reduced blood pressures (DSS), which occur on day 4 - 6 af-
ter the onset of fever [4, 6], were not significantly displayed 
by the patients during the early acute-phase who subsequent-
ly developed SDD (DHF/DSS). 
We believe that, despite studying only relatively low 
numbers of patients due to the present rarity of SDD in our 
study site, this is the first report in which clinical criteria 
were identified that, either alone or with further significant 
support by other clinical and hematological criteria, could 
definitively identify patients during the early acute phase of 
illness who subsequently developed SDD (DHF/DSS) ver-
sus N-SDD, or had a FUO.  This is also the first report to 
assess and identify conjunctival injection as a definitive cri-
terion for the identification of the patients who subsequently 
develop SDD. While relatively rare in our city, we believe 
that implementing such criteria to avert or lessen SDD symp-
toms using prompt appropriate therapies, will be important 
in this city, elsewhere in the Caribbean coast of Colombia, 
and possibly in the world. Further studies are therefore being 
conducted to test the prognostic accuracies of these criteria 
in other cities on the Caribbean coast of Colombia where 
SDD is also relative rare, as well as other cities in Colombia 
where SDD (DHF/DSS) cases are more common.
Acknowledgement
We thank Elsa de Plata (Secretaria Distrital Salud) and Na-
poleon de la Ossa (Universidad del Norte) for their help in 
the collection of the patients’ samples and clinical data. This 
study  received  financial  support  from  the  Departamento 
Admistrativo de Ciencia, Tecnologia e Innovacion (COL-
CIENCIAS) grant numbers 1215-04-14364 and 1215-40-
820551 and Proyecto Estrategico (Universidad del Norte). 
The funders however had no role in the study design, data 
collection and analysis, decision to publish, or preparation 
of the manuscript. 
Conflicts of Interest
The authors declare that no conflicts of interest exist.
Authors’ Contributions
AKIF and CMER equally contributed to the design of the 
study, execution of the laboratory work and the collection 
and analyses of the data, and AKIF wrote the manuscript.
 
References
1.  Gubler DJ. Dengue/dengue haemorrhagic fever: history 
and current status. Novartis Found Symp. 2006;277:3-
16; discussion 16-22, 71-13, 251-253.
2.  Kuno G. Factors influencing the transmission of dengue 
viruses. In: Gubler DJ, Kuno G, eds. Dengue and den-
gue hemorrhagic fever. New York: CAB International, 
1997:61-88.
3.  George R, Lum LCS. Clinical spectrum of dengue in-
fection. In: Gubler DJ, Kuno G, eds. Dengue and den-
gue hemorrhagic fever. New York: CAB International, 
1997:89-113.
4.  World Health Organization. Dengue haemorrhagic fe-
ver: diagnosis, treatment, prevention and control. Ge-
neva: World Health Organization, 1997.
5.  Gulati S, Maheshwari A. Atypical manifestations of 
dengue. Trop Med Int Health. 2007;12(9):1087-1095.
6.  World Health Organization. Dengue haemorrhagic fe-
ver: diagnosis, treatment, prevention and control. Ge-
neva: World Health Organization, 2009.
7.  Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya 
S, Chongswasdi V, Suntayakorn S, Puttisri P, et al. An 
enzyme-linked immunosorbent assay to characterize 
dengue infections where dengue and Japanese encepha-
litis co-circulate. Am J Trop Med Hyg. 1989;40(4):418-
427.
8.  Falconar AK, de Plata E, Romero-Vivas CM. Altered 
    41                                     42J Clin Med Res  •  2011;4(1):33-44    Dengue Virus Infections
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
enzyme-linked immunosorbent assay immunoglobulin 
M (IgM)/IgG optical density ratios can correctly classify 
all primary or secondary dengue virus infections 1 day 
after the onset of symptoms, when all of the viruses can 
be isolated. Clin Vaccine Immunol. 2006;13(9):1044-
1051.
9.  Halstead SB. Epidemiology of dengue and dengue hem-
orrhagic fever. In Dengue and dengue hemorrhagic fe-
ver. Ed Gubler DJ, Kuno G. New York, CAB Interna-
tional, 1997;23-44.
10.  Díaz-Quijanao FA, Martinez-Vega RA, Villar-Centeno 
LA. Early indicators of severity of dengue virus infec-
tions. Enferm Infecc Microbiol Clin 2005;23(9):529-
532.
11. Gonzalez AL, Martinez RA, Villar LA. Clinical evo-
lution of dengue in hospitalized patients. Biomedica. 
2008;28(4):531-543.
12. Ramirez-Zepeda MG, Velasco-Mondragon HE, Ramos 
C, Penuelas JE, Maradiaga-Cecena MA, Murillo-Llanes 
J,  Rivas-Llamas  R,  et  al.  Clinical  and  epidemiologic 
characteristics of dengue cases: the experience of a gen-
eral hospital in Culiacan, Sinaloa, Mexico. Rev Panam 
Salud Publica. 2009;25(1):16-23.
13.  Mourao  MP,  Lacerda  MV,  Macedo  VO,  Santos  JB. 
Thrombocytopenia in patients with dengue virus infec-
tion in the Brazilian Amazon. Platelets. 2007;18(8):605-
612.
14.  Tanner L, Schreiber M, Low JG, Ong A, Tolfvenstam T, 
Lai YL, Ng LC, et al. Decision tree algorithms predict 
the diagnosis and outcome of dengue fever in the early 
phase of illness. PLoS Negl Trop Dis. 2008;2(3):e196.
15.  Lee VJ, Lye DC, Sun Y, Leo YS. Decision tree algo-
rithm in deciding hospitalization for adult patients with 
dengue haemorrhagic fever in Singapore. Trop Med Int 
Health. 2009;14(9):1154-1159.
16.  Potts JA, Thomas SJ, Srikiatkhachorn A, Supradish PO, 
Li W, Nisalak A, Nimmannitya S, et al. Classification 
of dengue illness based on readily available laboratory 
data. Am J Trop Med Hyg. 2010;83(4):781-788.
17.  Potts JA, Gibbons RV, Rothman AL, Srikiatkhachorn A, 
Thomas SJ, Supradish PO, Lemon SC, et al. Prediction 
of dengue disease severity among pediatric Thai patients 
using  early  clinical  laboratory  indicators.  PLoS  Negl 
Trop Dis. 2010;4(8):e769.
18.  Rico-Hesse R, Harrison LM, Salas RA, Tovar D, Nisal-
ak A, Ramos C, Boshell J, et al. Origins of dengue type 
2 viruses associated with increased pathogenicity in the 
Americas. Virology. 1997;230(2):244-251.
19.  Usme-Ciro JA, Mendez JA, Tenorio A, Rey GJ, Domin-
go C, Gallego-Gomez JC. Simultaneous circulation of 
genotypes I and III of dengue virus 3 in Colombia. Virol 
J. 2008;5:101.
20. Aquino VH, Amarilla AA, Alfonso HL, Batista WC, 
Figueiredo LT. New genotype of dengue type 3 virus cir-
culating in Brazil and Colombia showed a close relation-
ship to old Asian viruses. PLoS One. 2009;4(10):e7299.
21.  Rosen  L.  Disease  exacerbation  caused  by  sequential 
dengue infections: myth or reality? Rev Infect Dis. 
1989;11 Suppl 4:S840-842.
22. Wichmann O, Hongsiriwon S, Bowonwatanuwong C, 
Chotivanich K, Sukthana Y, Pukrittayakamee S. Risk 
factors and clinical features associated with severe den-
gue infection in adults and children during the 2001 
epidemic in Chonburi, Thailand. Trop Med Int Health. 
2004;9(9):1022-1029.
23. Anantapreecha S, Chanama S, A An, Naemkhunthot S, 
Sa-Ngasang A, Sawanpanyalert P, Kurane I. Serologi-
cal and virological features of dengue fever and dengue 
haemorrhagic fever in Thailand from 1999 to 2002. Epi-
demiol Infect. 2005;133(3):503-507.
24.  Fried  JR,  Gibbons  RV,  Kalayanarooj  S,  Thomas  SJ, 
Srikiatkhachorn A, Yoon IK, Jarman RG, et al. Sero-
type-specific differences in the risk of dengue hemor-
rhagic fever: an analysis of data collected in Bangkok, 
Thailand  from  1994  to  2006.  PLoS  Negl  Trop  Dis. 
2010;4(3):e617.
25.  Fox A, Le NM, Simmons CP, Wolbers M, Wertheim HF, 
Pham TK, Tran TH, et al. Immunological and viral de-
terminants of dengue severity in hospitalized adults in 
Ha Noi, Viet Nam. PLoS Negl Trop Dis. 2011;5(3):e967.
26. Ocazionez RE, Gomez SY, Cortes FM. Dengue hem-
orrhagic fever serotype and infection pattern in a Co-
lombian  endemic  area.  Rev  Salud  Publica  (Bogota). 
2007;9(2):262-274.
27. Cordeiro MT, Schatzmayr HG, Nogueira RM, Oliveira 
VF, Melo WT, Carvalho EF. Dengue and dengue hem-
orrhagic fever in the State of Pernambuco, 1995-2006. 
Rev Soc Bras Med Trop. 2007;40(6):605-611.
28.  Cordeiro  MT,  Silva  AM,  Brito  CA,  Nascimento  EJ, 
Magalhaes MC, Guimaraes GF, Lucena-Silva N, et al. 
Characterization of a dengue patient cohort in Recife, 
Brazil. Am J Trop Med Hyg. 2007;77(6):1128-1134.
29.  Romero-Vivas CM, Leake CJ, Falconar AK. Determi-
nation of dengue virus serotypes in individual Aedes 
aegypti mosquitoes in Colombia. Med Vet Entomol. 
1998;12(3):284-288.
30.  Romero-Vivas CM, Sutherland CJ, Falconar AK. The 
use of direct sequencing of dengue virus cDNA from 
individual  field-collected  Aedes  aegypti  for  surveil-
lance and epidemiological studies. Med Vet Entomol. 
2000;14(1):89-94.
31. Mendez A, Gonzalez G. Dengue haemorrhagic fever in 
children: ten years of clinical experience. Biomedica. 
2003;23(2):180-193.
32. Mendez A, Gonzalez G. Abnormal clinical manifesta-
tions of dengue hemorrhagic fever in children. Biomed-
ica. 2006;26(1):61-70.
33.  Salgado DM, Rodriguez JA, Garzon M, Cifuentes G, 
    43                                     44J Clin Med Res  •  2011;4(1):33-44 Falconar et al
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
Ibarra M, Vega MR, Castro D. Clinical and epidemio-
logical characterisation of dengue haemorrhagic fever 
in Neiva, Colombia, 2004. Rev Salud Publica (Bogota). 
2007;9(1):53-63.
34.  Salgado DM, Eltit JM, Mansfield K, Panqueba C, Castro 
D, Vega MR, Xhaja K, et al. Heart and skeletal muscle 
are targets of dengue virus infection. Pediatr Infect Dis 
J. 2010;29(3):238-242.
35.  Villabona-Arenas  CJ,  Miranda-Esquivel  DR,  Jimenez 
RE. Phylogeny of dengue virus type 3 circulating in Co-
lombia between 2001 and 2007. Trop Med Int Health. 
2009;14(10):1241-1250.
36.  Mendez JA, Usme-Ciro JA, Domingo C, Rey GJ, San-
chez JA, Tenorio A, Gallego-Gomez JC. Phylogenetic 
history demonstrates two different lineages of dengue 
type 1 virus in Colombia. Virol J. 2010;7:226.
37.  Arboleda M, Campuzano M, Restrepo BN, Cartagena G. 
[The clinical behavior of dengue in patients hospitalized 
in the Antonio Roldan Betancur Hospital of Apartado, 
Antioquia, 2000]. Biomedica. 2006;26(2):286-294.
38.  Villar-Centeno  LA,  Diaz-Quijano  FA,  Martinez-Vega 
RA. Biochemical alterations as markers of dengue hem-
orrhagic fever. Am J Trop Med Hyg. 2008;78(3):370-
374.
39.  Passos SR, Bedoya SJ, Hokerberg YH, Maia SC, Georg 
I, Nogueira RM, Souza RV, et al. Clinical and laboratory 
signs as dengue markers during an outbreak in Rio de 
Janeiro. Infection. 2008;36(6):570-574.
40.  Diaz-Quijano  FA,  Villar-Centeno  LA,  Martinez-Vega 
RA. Predictors of spontaneous bleeding in patients with 
acute febrile syndrome from a dengue endemic area. J 
Clin Virol. 2010;49(1):11-15.
41.  Potts  JA,  Rothman  AL.  Clinical  and  laboratory  fea-
tures that distinguish dengue from other febrile ill-
nesses in endemic populations. Trop Med Int Health. 
2008;13(11):1328-1340.
42. Aziz MM, Hasan KN, Hasanat MA, Siddiqui MA, Sa-
limullah M, Chowdhury AK, Ahmed M, et al. Predomi-
nance of the DEN-3 genotype during the recent dengue 
outbreak in Bangladesh. Southeast Asian J Trop Med 
Public Health. 2002;33(1):42-48.
43.  Gunther J, Ramirez-Palacio LR, Perez-Ishiwara DG, Sa-
las-Benito JS. Distribution of dengue cases in the state 
of Oaxaca, Mexico, during the period 2004-2006. J Clin 
Virol. 2009;45(3):218-222.
44.  Worobey M, Rambaut A, Holmes EC. Widespread intra-
serotype recombination in natural populations of dengue 
virus. Proc Natl Acad Sci U S A. 1999;96(13):7352-
7357.
45.  Chen SP, Yu M, Jiang T, Deng YQ, Qin CF, Han JF, 
Qin ED. Identification of a recombinant dengue virus 
type 1 with 3 recombination regions in natural popu-
lations in Guangdong province, China. Arch Virol. 
2008;153(6):1175-1179.
46.  Perez-Ramirez G, Diaz-Badillo A, Camacho-Nuez M, 
Cisneros A, Munoz Mde L. Multiple recombinants in 
two dengue virus, serotype-2 isolates from patients from 
Oaxaca, Mexico. BMC Microbiol. 2009;9:260.
47. Falconar AK, Martinez F. The NS1 glycoprotein can 
generate dramatic antibody-enhanced dengue viral repli-
cation in normal out-bred mice resulting in lethal multi-
organ disease. PLoS One. 2011;6(6):e21024.
48.  Stephens HA. HLA and other gene associations with 
dengue disease severity. Curr Top Microbiol Immunol. 
2010;338:99-114.
49.  LaFleur C, Granados J, Vargas-Alarcon G, Ruiz-Morales 
J, Villarreal-Garza C, Higuera L, Hernandez-Pacheco G, 
et al. HLA-DR antigen frequencies in Mexican patients 
with dengue virus infection: HLA-DR4 as a possible 
genetic resistance factor for dengue hemorrhagic fever. 
Hum Immunol. 2002;63(11):1039-1044.
50.  Falcon-Lezama JA, Ramos C, Zuniga J, Juarez-Palma 
L, Rangel-Flores H, Garcia-Trejo AR, Acunha-Alonzo 
V, et al. HLA class I and II polymorphisms in Mexi-
can Mestizo patients with dengue fever. Acta Trop. 
2009;112(2):193-197.
51. de la C Sierra B, Kouri G, Guzman MG. Race: a risk 
factor for dengue hemorrhagic fever. Arch Virol. 
2007;152(3):533-542.
52.  Blanton RE, Silva LK, Morato VG, Parrado AR, Dias JP, 
Melo PR, Reis EA, et al. Genetic ancestry and income 
are associated with dengue hemorrhagic fever in a highly 
admixed population. Eur J Hum Genet. 2008;16(6):762-
765.
53. Holmes EC. RNA virus genomics: a world of possibili-
ties. J Clin Invest. 2009;119(9):2488-2495.
    43                                     44